On October 26, 2020, the Second Circuit affirmed a decision by the SDNY in favor of Pfizer subsidiary Hospira in a commercial dispute brought against Hospira by Apotex Corp. In 2019, the trial court granted Hospira’s motion to dismiss various tort claims and accompanying damages theories, a decision now affirmed by the Second Circuit; and in January 2020, the trial court granted Hospira’s motion to dismiss Apotex’s antitrust claims, a decision Apotex did not appeal. With these wins, the dispute is narrowed to a few state law claims in state court in New York. Luke McCloud of Williams & Connolly argued before the Second Circuit; the Williams & Connolly team also included associates Paul Ream and Wendy Zupac, as well as partners Ana Reyes, and Heidi Hubbard.
Click here to read coverage from Law360.